Publications

With the goal of preventing more hip fractures, a next generation of the VirtuOst® Biomechanical Computed Tomography (BCT) test was developed that integrates measurements from a clinical CT scan related to fall risk, impact force, and femoral strength, the three main determinants of hip fracture. Here, we introduce the test and validate it against bone mineral density (BMD) and FRAX®. Our source population from a large healthcare system comprised of 341,364 patients (≥ 65 years) with an abdominal-pelvic CT during care. Using data from 3,035 patients (1,790 with hip fracture), we developed a "BCT Risk Score" (range: 0-100) having input risk factors of age, femoral strength, ratio of trabecular/cortical BMD, muscle area, intramuscular fat, femoral neck volume, hip width, and posterior fat thickness. In a geographically distinct set of 2,124 patients (1,293 with hip fracture), we then compared the BCT Risk Score against a DXA-equivalent hip BMD T-score (lowest hip value, measured from the CT scan by VirtuOst) and FRAX hip fracture risk (with BMD but without parental fracture history) for predicting a first incident hip fracture within five years. For the women, the c-statistic for predicting fracture was higher for BCT (0.89, 95% confidence interval 0.87-0.90) than for BMD (0.81, 0.79-0.84) or FRAX (0.85, 0.83-0.87). Using binary thresholds to identify high-risk patients, sensitivity for BCT (Risk Score ≥ 75) was higher than for BMD (T-score ≤ -2.5) and FRAX (hip risk ≥ 3.0%): 81.4% vs. 47.8% vs. 75.9%, respectively; positive predictive values confirmed comparable high-risk status (BCT 13.6% vs. BMD 15.3% vs. FRAX 12.7%). Similar trends were observed for the men, two-year outcomes, and identifying very-high-risk patients. We conclude that, compared to both BMD and FRAX, the integrative BCT test better predicted hip fracture and its high sensitivity should improve fracture prevention.

Emerging anti-osteoporosis therapies might present varied mechanisms of action and demand active control groups or sequential therapies due to ethical or mechanistic reasons. We previously showed a strong association between treatment-induced changes in total hip bone mineral density(THBMD) at 12 and 24 mo and reduced fracture risk in placebo-controlled trials. We determined the surrogate threshold effect(STE): the minimum THBMD difference (active-placebo) in a trial that would predict a significant reduction in fracture risk in trials. In this analysis, we investigated whether these associations are influenced by drug mechanism of action or trial design, including treatment with an anabolic followed by an anti-resorptive compared to active control or placebo. We analyzed individual patient data from 22 randomized, placebo-controlled trials (17 anti-resorptive, 3 PTH analogues, 1 odanacatib, and 1 romosozumab placebo-controlled phase), and three trials of an anabolic followed by an anti-resorptive(1 PTH analogue and 2 romosozumab). We established treatment-related differences in THBMD changes, calculated fracture risk reductions for radiologic vertebral and all clinical fractures, and estimated study-level associations between these features via meta-regression. We found consistent associations between treatment-related THBMD changes and fracture risk reduction across different drug mechanisms and trial designs. Among placebo-controlled trials, the r2 values for vertebral fractures were 0.73(p = .0001) and 0.78(p = .0002) at 24 mo, and 0.59(p = .0003) and 0.70(p = .0007) at 12 mo for all drugs versus only anti-resorptive drugs, respectively. Similarly, for all clinical fractures, the r2 were 0.71(p < .0001) and 0.65(p = .0009) at 24 mo and 0.46(p = .0007) and 0.51(p = .002) at 12 mo for all drugs versus only anti-resorptive drugs. For trials of an anabolic followed by an anti-resorptive, the association between THBMD change and fracture risk reduction was similar to that for the placebo-controlled monotherapy trials. Our analyses indicate robust associations between treatment-induced THBMD changes and fracture risk reduction across various anti-osteoporosis therapies and trial designs, suggesting that treatment-induced changes in THBMD predict anti-fracture efficacy regardless of drug mechanism or trial design.

Osteogenesis imperfecta (OI) is a group of diseases caused by defects in type I collagen processing which result in skeletal fragility. While these disorders have been regarded as defects in osteoblast function, the role of matrix-embedded osteocytes in OI pathogenesis remains largely unknown. Homozygous human SP7 (c.946 C > T, R316C) mutation results in a recessive form of OI characterized by fragility fractures, low bone mineral density and osteocyte dendrite defects. To better understand how the OI-causing R316C mutation affects the function of SP7, we generated Sp7R342C knock-in mice. Consistent with patient phenotypes, Sp7R342C/R342C mice demonstrate increased cortical porosity and reduced cortical bone mineral density. Sp7R342C/R342C mice show osteocyte dendrite defects, increased osteocyte apoptosis, and intracortical bone remodeling with ectopic intracortical osteoclasts and elevated osteocyte Tnfsf11 expression. Remarkably, these defects in osteocyte function contrast to only mild changes in mature osteoblast function, suggesting that this Sp7 mutation selectively interferes with the function of Sp7 in osteocytes and mature osteoblasts, but not during early stages of osteoblast differentiation. Osteocyte morphology changes in Sp7R342C/R342C mice were not restored by inhibiting osteoclast formation, indicating that dendrite defects lie upstream of high intracortical osteoclast activity in this model. Moreover, transcriptomic profiling reveals that the expression of a core set osteocyte-enriched genes is highly dysregulated by the R342C mutation. Thus, this supports a model in which osteocyte dysfunction can drive OI pathogenesis and provides a valuable resource to test novel therapeutic approaches and to understand the osteocyte-specific role of SP7 in bone remodeling.

Both type 1 diabetes (T1D) and type 2 diabetes (T2D) increase hip fracture risk beyond what bone mineral density (BMD) explains, potentially due to changes in bone material from advanced glycation end-products (AGEs) and altered matrix composition. However, there are limited data regarding the impact of diabetes on human trabecular bone composition and mechanical behavior. We assessed trabecular bone material behavior using cadaveric femoral specimens from older adults with long-duration T1D (≥50 years; n = 24), T2D (n = 21), and non-diabetic controls (n = 21). Femoral head trabecular bone was evaluated via micro-computed tomography, mechanical testing (uniaxial compression), total fluorescent AGEs quantification, and Raman spectroscopy (matrix composition). BMD and microarchitecture measures did not differ between groups (p > 0.535). Compared to controls, T1D trabecular bone had higher AGE content (+42 %, p = 0.016), lower mineral-to-matrix ratio (-12 %, p = 0.048), trend toward lower crystallinity (-4 %, p = 0.054), and greater proline hydroxylation (+5 %, p = 0.007), but showed no differences in mechanical behavior (p ≥ 0.415). T2D trabecular bone also had elevated AGE (+60 %, p < 0.001) and altered matrix composition. Unlike T1D, T2D bone demonstrated improved ductility and post-yield energy dissipation versus control, with greater ultimate strain (+36 %, p = 0.008), post-yield strain (+62 %, p = 0.075), and toughness to ultimate force (+38 %, p = 0.044). This study reveals distinct effects of T1D and T2D on trabecular bone matrix composition, although these effects did not coincide with reduced mechanical properties under uniaxial compression loading.

The increase in chest CT volumes affords radiologists the opportunity to systematically assess imaging biomarkers including coronary and thoracic arterial calcification, emphysema, airway dysanapsis, adipose tissue in various compartments, skeletal muscle (in terms of both quantity and quality), and vertebral body bone attenuation (as a measure of bone mineral density), extending from the T1 through T12 vertebral body levels (1). These biomarkers represent a spectrum of disease-induced changes or increases in risk for developing disease. This Special Series review provides an overview of these established and emerging imaging biomarkers on chest CT scans, aiming to serve as a reference for practicing radiologists. We discuss the imaging biomarkers' importance for patient care, highlight recent developments, present approaches for interpretation and integration into clinical workflows with attention to the role of reference values, consider challenges in serial assessment resulting from variations in technical parameters, describe the biomarkers' incorporation into societal guidelines, and summarize FDA-approved AI tools to aid evaluation.

BACKGROUND: Bone stress injury (BSI) is a common overuse injury in female athletes that can occur in a variety of bones, including both proximal (pelvis, sacrum, femoral neck) or distal (tibia, fibula, metatarsals) locations. Prior work has demonstrated differences in running biomechanics in those with BSI; however, this was not separated by anatomy. We hypothesised that both female athletes with distal BSI and female athletes with proximal BSI would have lower cadence, higher centre of mass (COM) and lower duty factor than those without prior BSI.

METHODS: Cross-sectional study of 45 female athletes (15 with prior distal BSI, 15 with prior proximal BSI and 15 with no BSI history). Each ran on an instrumented treadmill at self-selected and 5-kilometre race speeds, with data collected in a fresh and exerted state. A series of analysis of variance tests (ANOVAs, group by condition) were used to analyse the results.

RESULTS: Participants with previous proximal BSI ran with greater vertical COM excursion compared with those with no previous BSI at race speed (10.2±1.7 cm vs 8.5±0.8 cm (p<0.001)). The proximal BSI population had a lower cadence than the no prior BSI population at race speed (170±13 steps per minute vs 180±10 steps per minute (p=0.012)). Duty factor was lower in the proximal BSI group compared with the distal BSI group at the race speed (32±3% vs 34±3% (p=0.013)).

CONCLUSION: COM and cadence should be further investigated for association with proximal BSI.

IMPORTANCE: Musculoskeletal injuries (MSKIs) are pervasive problems in novice training environments. Evaluation of modifiable and nonmodifiable risk factors of MSKI risk prior to entry into these environments is largely understudied.

OBJECTIVE: To provide military leaders, civilian and military clinicians, and physical training instructors with an MSKI risk model for identifying low-, moderate-, and high-risk profiles among individuals starting US Army Basic Combat Training (BCT) or a physical training program.

DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study, data collection was conducted between August 5, 2017, and April 15, 2023, at 2 US Army BCT sites. The sample consisted of volunteer trainees between the ages of 17 and 41 years. They were followed up from the start of BCT. Data analyses were conducted from April to September 2024.

EXPOSURES: Data for the factors potentially associated with MSKI were collected during the first week of BCT and included blood draws, total body dual-energy x-ray absorptiometry, and muscle power test results; surveys of demographics, medical history, physical activity, psychological characteristics, and sleep patterns; and physical fitness results.

MAIN OUTCOMES AND MEASURES: MSKIs identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. Logistic regression-based models estimating the risk of MSKI were generated using 5-fold internal cross-validation for the total cohort, males, and females. Traffic light model examples of low (green), moderate (amber), and high (red) MSKI risk tiers were produced.

RESULTS: In this cohort study of 2988 Army trainees (median [IQR] age, 19.0 [19.0-22.0] years; 1880 males [62.9%]), 729 females (49.0%) and 758 males (51.0%) had an ICD-10 code-identified MSKI, and 1067 (35.7%) had more than 1 ICD-10 code-identified MSKI. Factors associated with increased MSKI risk in the total cohort and female- and male-specific MSKI risk models (with areas under the receiver operator characteristic curve of 0.701, 0.678, and 0.661, respectively) encompassed 7 variable categories: demographics; anthropometrics and body composition; nutritional status; medical and health history; history of sports and past or current physical activity or fitness; psychological factors (ie, pain, grit, and hardiness); and sleep parameters.

CONCLUSIONS AND RELEVANCE: This cohort study presents a tiered approach to identifying persons at increased MSKI risk before the start of a physical training program. Applying a tiered quantification risk metric and incorporating multifactorial interventions from these findings may play a role in reduced MSKI risk.

Parathyroid hormone (PTH) analogs with improved actions in vivo could lead to optimized treatments for bone and mineral ion diseases. Rapid clearance from the circulation and short dwell times on the PTH receptor limit the efficacies of conventional PTH peptides currently in medical use. Here, we seek to enhance PTH peptide efficacy using two distinct peptide lipidation strategies. First, we append a lipid chain to the peptide's C-terminus in a fashion to promote binding to serum albumin and hence prolong the peptide's circulation half-life in vivo. Second, we append a lipid chain to a lysine side chain in a fashion designed to anchor the peptide to the cell membrane as the ligand is bound to the receptor and hence increase its dwell time on the receptor. We find that both strategies of lipidation can profoundly enhance the efficacy of PTH peptides in vitro and in mice. Our results could lead to the development of modified PTH analogs with optimized therapeutic utility.

Bariatric surgeries such as Roux-en-Y gastric bypass (RYGB) and adjustable gastric banding (AGB) lead to long-term deficits in bone density but are also accompanied by decreased weight, which may lower the impact force with falls. The aim of this study was to compare the long-term skeletal impact of RYGB and AGB using a biomechanical evaluation of load-to-strength ratio at the distal radius as a surrogate for wrist fracture risk. We conducted a cross-sectional study evaluating bone microarchitectural parameters and bone turnover in adults who received either RYGB or AGB surgery ≥10 yr ago (RYGB: n = 22; AGB: n = 23). Bone strength at the distal radius was estimated by microfinite element analysis from HR-pQCT. We used a single-spring biomechanical model to estimate impact force and then calculated load-to-strength ratio as a ratio of impact force to bone strength, with higher load-to-strength ratios representing a higher susceptibility to fracture. In multivariable analyses, the RYGB group had higher bone resorption marker C-telopeptide (CTX) levels, lower volumetric bone density, and worse cortical and trabecular microarchitectural parameters than the AGB group. Furthermore, estimated bone strength at the radius was lower in the RYGB group (3725 ± 139 N vs 4141 ± 157 N, p = .030), and the load-to-strength ratio was higher in RYGB group as compared with AGB (0.84 ± 0.04 vs 0.72 ± 0.05, p = .035), suggestive of higher propensity for wrist fracture. Taken together, these results indicate the long-term deleterious skeletal effects are more concerning with RYGB than AGB.